Daewoong Pharmaceutical (Co-CEOs Seongsu Park and Changjae Lee) announced on June 11 that it has signed a joint research agreement with Swedish biotechnology company Salipro Biotech to accelerate the development of next-generation therapeutics.

Under the agreement, Salipro will provide Daewoong with access to its proprietary Salipro® Platform, a technology designed to stabilize membrane proteins. Daewoong plans to apply this platform to enhance the targeting of membrane protein drug candidates and speed up the discovery of innovative therapies.

“Membrane proteins are essential for cellular signaling and substance transport, accounting for over 60% of all drug targets,” said a Daewoong representative. “However, due to their instability outside the cell, they have been difficult to study. The Salipro® Platform overcomes this challenge by maintaining protein structure in a near-native environment.”

Jens Frauenfeld, CEO of Salipro Biotech, added, “This is our first partnership with a Korean pharmaceutical company, making it especially meaningful. The Salipro® Platform enables access to previously undruggable targets, creating new possibilities in global drug development.”

Seongsu Park, CEO of Daewoong Pharmaceutical, stated, “We believe this collaboration will significantly enhance our membrane protein research capabilities and accelerate drug development. Through open innovation, we aim to deliver first-in-class therapies to the global market.”